NovoCure Limited
NVCR
$15.21
$3.2827.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.21% | -18.60% | -1.33% | 14.82% | 18.55% |
| Total Depreciation and Amortization | 33.09% | 27.00% | 10.45% | 6.01% | 1.76% |
| Total Amortization of Deferred Charges | 0.19% | 12.06% | 12.06% | 12.06% | 12.06% |
| Total Other Non-Cash Items | -32.02% | 49.62% | 50.96% | 40.94% | 45.82% |
| Change in Net Operating Assets | -450.15% | -101.34% | -420.91% | -237.91% | -112.30% |
| Cash from Operations | -85.94% | 8.00% | 33.48% | 65.46% | 64.04% |
| Capital Expenditure | 37.82% | 24.65% | 4.24% | -27.12% | -58.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 576.37% | 416.12% | 114.26% | -192.22% | -146.10% |
| Cash from Investing | 411.80% | 503.15% | 240.35% | -212.89% | -176.16% |
| Total Debt Issued | 3.15% | 3.15% | -100.00% | -- | -- |
| Total Debt Repaid | -4,244.03% | 100.00% | 100.00% | -430,333.33% | -129,030.00% |
| Issuance of Common Stock | 54.92% | 96.29% | 57.82% | 5.01% | -60.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -599.74% | 23.78% | -88.50% | 783.19% | 472.08% |
| Foreign Exchange rate Adjustments | 326.44% | 122.08% | 1,603.33% | 220.59% | -232.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.00% | 375.54% | -248.96% | -221.13% | -160.34% |